Anita Schumacher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anita Schumacher has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
H. Arnesen
Centre for Clinical Research, Ulleval University Hospital, Oslo, Norway
3 shared publicationsI. Seljeflot
Centre for Clinical Research, Ulleval University Hospital, Oslo, Norway
3 shared publicationsJ. E. Otterstad
Department of Microbiology and Department of Medicine, Vestfold Central Hospital, Tønsberg, Norway
3 shared publicationsL. Sommervoll
Department of Microbiology and Department of Medicine, Vestfold Central Hospital, Tønsberg, Norway
3 shared publicationsA. B. Lerkerød
Department of Microbiology and Department of Medicine, Vestfold Central Hospital, 3116 Tønsberg,1 and Center for Clinical Research and Life Insurance Companies' Institute for Medical Statistics, Ullevål University Hospital, 0407 Oslo,2 Norway
1 shared publicationA.B Lerkerød
1 shared publication
Latest Publications
- Open Access
- 1 October 2002
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 8 (10) , 654-661
Does infection with Chlamydia pneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesion molecules in humans?
- 1 October 2002
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 8 (10) , 654-661
Open AccessDoes infection with Chlamydia pneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesion molecules in humans?
- 1 September 2002
- Published by Elsevier in Atherosclerosis
- Vol. 164 (1) , 153-160
Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease
- 1 September 2002
- Published by Elsevier in Atherosclerosis
- Vol. 164 (1) , 153-160
Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease
- 1 January 2002
- Published by Elsevier in Thrombosis Research
- Vol. 105 (1) , 25-31
Increased levels of endothelial haemostatic markers in patients with coronary heart disease
- 1 January 2002
- Published by Elsevier in Thrombosis Research
- Vol. 105 (1) , 25-31
Increased levels of endothelial haemostatic markers in patients with coronary heart disease
- 1 January 2002
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 62 (1) , 59-68
Increased levels of markers of vascular inflammation in patients with coronary heart disease
Elevated levels of soluble cell adhesion molecules (sCAMs), inflammatory cytokines and C-reactive protein (CRP) have been associated with atherosclerotic disease states. The aim of the present study was to evaluate whether circulating levels of vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (sICAM-1), E- and P-selectin were significantly elevated in patients with coronary heart disease (CHD) compared with healthy controls, and to study possible associations between these sCAMs, tumour necrosis factor f (TNF f ), interleukin-6 (IL-6), CRP and major CHD risk factors. The study included 193 patients in various stages of CHD and 193 matched controls. To evaluate any possible influence of acute phase reaction, reinvestigation was performed after 6 months. After adjustment for major CHD risk factors, sVCAM-1, sICAM-1, P-selectin, IL-6 and CRP remained significantly elevated in the CHD patients (p for all < 0.001). In multivariate analysis sVCAM-1 was predicted by age (p = 0.015), sICAM-1 by smoking (p < 0.001) and total cholesterol (p = 0.026), E-selectin by body mass index (BMI) (p = 0.004) and P-selectin by male gender (p = 0.015). TNF f significantly predicted sICAM-1 and E-selectin levels, while IL-6 predicted CRP but none of the sCAMs measured. This might indicate that TNF f, but not IL-6, plays a major role in the regulation of sCAM levels in vivo .
- 1 January 2002
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 62 (1) , 59-68
Increased levels of markers of vascular inflammation in patients with coronary heart disease
Elevated levels of soluble cell adhesion molecules (sCAMs), inflammatory cytokines and C-reactive protein (CRP) have been associated with atherosclerotic disease states. The aim of the present study was to evaluate whether circulating levels of vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (sICAM-1), E- and P-selectin were significantly elevated in patients with coronary heart disease (CHD) compared with healthy controls, and to study possible associations between these sCAMs, tumour necrosis factor f (TNF f ), interleukin-6 (IL-6), CRP and major CHD risk factors. The study included 193 patients in various stages of CHD and 193 matched controls. To evaluate any possible influence of acute phase reaction, reinvestigation was performed after 6 months. After adjustment for major CHD risk factors, sVCAM-1, sICAM-1, P-selectin, IL-6 and CRP remained significantly elevated in the CHD patients (p for all < 0.001). In multivariate analysis sVCAM-1 was predicted by age (p = 0.015), sICAM-1 by smoking (p < 0.001) and total cholesterol (p = 0.026), E-selectin by body mass index (BMI) (p = 0.004) and P-selectin by male gender (p = 0.015). TNF f significantly predicted sICAM-1 and E-selectin levels, while IL-6 predicted CRP but none of the sCAMs measured. This might indicate that TNF f, but not IL-6, plays a major role in the regulation of sCAM levels in vivo .
- Open Access
- 1 May 2001
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 39 (5) , 1859-1864
Chlamydia pneumoniae Serology: Importance of Methodology in Patients with Coronary Heart Disease and Healthy Individuals
Most publications on the relationship between infection with Chlamydia pneumoniae and coronary heart disease (CHD) propose an association, but negative studies are also reported. Seroepidemiological studies vary in the use of different serological methods, different cutoff limits, different sampling times in relation to acute cardiac events, and different clinical stages of CHD. We wanted to compare three different commercially available methods for measuring Chlamydia antibodies to see how the choice of method influenced the prevalence of seropositive individuals in CHD patients and in healthy individuals and to see if sampling time in relation to an acute cardiac event or the stage of atherothrombotic disease influenced the results. Blood samples from 197 CHD patients and 197 individually matched healthy control individuals were tested at baseline and after 6 months; the mean age was 55 years in both groups, and 18% were women. Among the CHD patients, 166 were included at a median of 16 days after an acute cardiac event and 31 had chronic disease with the latest acute event being >3 months earlier. The difference in prevalence of antibodies between the CHD patients and the healthy controls was significant when Chlamydia lipopolysaccharide antibodies were measured, while no significant differences between the study groups were observed by the two methods detecting Chlamydia pneumoniae major outer membrane protein antibodies. The number of seropositive individuals was quite similar at inclusion and 6 months later, and no significant differences were observed between patients with a recent cardiac event and those with a more remote cardiac event. We conclude that the choice of serological method is of major importance when evaluating a possible relationship between C. pneumoniae and CHD.
- 1 May 2001
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 39 (5) , 1859-1864
Open AccessChlamydia pneumoniae Serology: Importance of Methodology in Patients with Coronary Heart Disease and Healthy Individuals
Most publications on the relationship between infection with Chlamydia pneumoniae and coronary heart disease (CHD) propose an association, but negative studies are also reported. Seroepidemiological studies vary in the use of different serological methods, different cutoff limits, different sampling times in relation to acute cardiac events, and different clinical stages of CHD. We wanted to compare three different commercially available methods for measuring Chlamydia antibodies to see how the choice of method influenced the prevalence of seropositive individuals in CHD patients and in healthy individuals and to see if sampling time in relation to an acute cardiac event or the stage of atherothrombotic disease influenced the results. Blood samples from 197 CHD patients and 197 individually matched healthy control individuals were tested at baseline and after 6 months; the mean age was 55 years in both groups, and 18% were women. Among the CHD patients, 166 were included at a median of 16 days after an acute cardiac event and 31 had chronic disease with the latest acute event being >3 months earlier. The difference in prevalence of antibodies between the CHD patients and the healthy controls was significant when Chlamydia lipopolysaccharide antibodies were measured, while no significant differences between the study groups were observed by the two methods detecting Chlamydia pneumoniae major outer membrane protein antibodies. The number of seropositive individuals was quite similar at inclusion and 6 months later, and no significant differences were observed between patients with a recent cardiac event and those with a more remote cardiac event. We conclude that the choice of serological method is of major importance when evaluating a possible relationship between C. pneumoniae and CHD.